Matching articles for "Entereg"
Naloxegol (Movantik) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • September 28, 2015; (Issue 1478)
The FDA has approved naloxegol (Movantik –
AstraZeneca), a pegylated derivative of the opioid
antagonist naloxone, for oral treatment of opioid-induced
constipation in adults with chronic noncancer
pain....
The FDA has approved naloxegol (Movantik –
AstraZeneca), a pegylated derivative of the opioid
antagonist naloxone, for oral treatment of opioid-induced
constipation in adults with chronic noncancer
pain. It is the only oral opioid antagonist approved for
this indication in the US.
Alvimopan (Entereg) for Postoperative Ileus
The Medical Letter on Drugs and Therapeutics • December 1, 2008; (Issue 1300)
The FDA has approved the marketing of alvimopan (Entereg - Adolor/GlaxoSmithKline), a selective muopioid receptor antagonist, for oral treatment of postoperative ileus after bowel resection. The only other drug...
The FDA has approved the marketing of alvimopan (Entereg - Adolor/GlaxoSmithKline), a selective muopioid receptor antagonist, for oral treatment of postoperative ileus after bowel resection. The only other drug in this class available in the US is subcutaneously injected methylnaltrexone (Relistor), which is approved for treatment of opioid-induced constipation in patients with advanced illness receiving palliative care.
Methylnaltrexone (Relistor) for Opioid-Induced Constipation
The Medical Letter on Drugs and Therapeutics • August 11, 2008; (Issue 1292)
The FDA has approved subcutaneous injection of methylnaltrexone (Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced...
The FDA has approved subcutaneous injection of methylnaltrexone (Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced illness (such as incurable cancer or end-stage chronic obstructive pulmonary disease) who are receiving palliative care.